tarık onur Tiryaki

Dr. tarık onur Tiryaki

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2022 in Clinical Lymphoma Myeloma and Leukemia
Verified
Journal Article
Closed access
SASeval Akpinar
Seval Akpinar
MDMehmet Hilmi Dogu
Mehmet Hilmi Dogu
SÇSerhat Çelik
Serhat Çelik
OEOmer Ekinci
Omer Ekinci
IHIpek Yonal Hindilerden
Ipek Yonal Hindilerden
FAFevzi Altuntas
Fevzi Altuntas

24 January 2023 in BMC Cancer
Verified
Journal Article
Open access
PDF file
TTtarık onur Tiryaki
tarık onur Tiryaki
SÖSıdıka Gülkan Özkan
Sıdıka Gülkan Özkan
SESimge Erdem
Simge Erdem
AAAynur Dağlar Aday
Aynur Dağlar Aday
IHİpEk Yönal Hindilerden
İpEk Yönal Hindilerden
AYAkif Selim Yavuz
Akif Selim Yavuz
Mastocytosis is a very rare disorder and is divided into three prognostically distinct variants by World Health Organization: Cutaneous mastocytosis (CM), systemic mastocytosis (SM), and mast cell sarcoma or localized mast cell (MC) tumors. The wide range of complaints may cause patients to consult various clinics, with resulting mis- or underdiagnosis. Therefore, cooperation between different subspecialties is of paramount importance. In this article, we have compiled 104 adult mastocytosis cases diagnosed and followed in our Hematology and other clinics. 86 (82.7%) of 104 patients had systemic mastocytosis. Osteoporosis, disease-related complications, and secondary malignancies are important topics in this group. We know that indolent form has great survival. But smoldering or aggressive mastocytosis has a poor prognosis. CM and indolent SM have a significantly better prognosis compared to aggressive SM (p < 0.001). We found that the presence of more than 25% of mast cells in the bone marrow, the presence of concomitant marrow dysplasia, and the presence of disease-related complications affect survival (p < 0.001). In addition to the WHO classification, the IPSM scoring system is indicative of the prognosis in this rare disease.

18 July 2020 in Case Reports in Hematology
Verified
Journal Article
Open access
PDF file
MEMert Erciyestepe
Mert Erciyestepe
TTtarık onur Tiryaki
tarık onur Tiryaki
IHİpEk Yönal Hindilerden
İpEk Yönal Hindilerden
GYGülçin Yeğen
Gülçin Yeğen
MNMeliha Nalçacı
Meliha Nalçacı
Multiple myeloma is a type of plasma cell disorder and can be seen in different forms. According to current knowledge, it is not a curable disease. Smoldering multiple myeloma (SMM) is an asymptomatic clonal plasma cell disorder and distinguished from monoclonal gammopathy of undetermined significance by a much higher risk of progression to multiple myeloma. We present a 53-year-old female patient who started with SMM which turned into multiple myeloma after four years. Despite 26 cycles of lenalidomide treatment, we performed the second autologous stem transplantation. After 12 years from the diagnosis of the disease, it was transformed into plasma cell leukemia and widespread nodular lesions were seen in the liver. Different presentations could be seen due to malignant plasma cell infiltrations or primary amyloidosis. Liver involvement is one of them and is less common than other organ involvement. We report a case of myeloma presenting with extensive nodular involvement in the liver and misdiagnosed as metastatic disease. It is important because of its rarity and change of the treatment approach.

2 June 2021 in Turkish Journal of Hematology
Verified
Journal Article
Open access
TTtarık onur Tiryaki
tarık onur Tiryaki
KAKadir Uluç Anıl
Kadir Uluç Anıl
MBMelek Büyük
Melek Büyük
AYAhmet Yasir Yıldırım
Ahmet Yasir Yıldırım
AAAlp Atasoy
Alp Atasoy
SBSevgi Kalayoglu Besısık
Sevgi Kalayoglu Besısık

11 April 2022 in Nutrition
Verified
Journal Article
Closed access
BSBulent Saka
Bulent Saka
MBMurat Bektas
Murat Bektas
OBOguz Kagan Bakkaloglu
Oguz Kagan Bakkaloglu
SAShirkhan Amikishiyev
Shirkhan Amikishiyev
GSGöktug Sarıbeyliler
Göktug Sarıbeyliler
TATimur Selcuk Akpınar
Timur Selcuk Akpınar

13 April 2025 in Bone Marrow Transplantation
Verified
Journal Article
Open access
PDF file
AKABDULLAH KARAKUS
ABDULLAH KARAKUS
TTTayfur Toptas
Tayfur Toptas
MDMehmet Sinan Dal
Mehmet Sinan Dal
ADAli Durdu
Ali Durdu
UHUgur Hatipoglu
Ugur Hatipoglu
FAFevzi Altuntas
Fevzi Altuntas
In this study, we aimed to compare the engraftment days, graft-versus-host disease (GVHD) development, relapse and overall survival rates in patients using myeloablative/reduced intensity conditioning regimens with posttransplant cyclophosphamide (PTCy) 25 mg/kg x2 with Anti-T lymphocyte Globulin (ATLG) (n = 29) and PTCy 50 mg/kg x2 doses (n = 41) in patients with acute leukemias. Matched related, matched unrelated, 1 mismatched unrelated, and haploidentical donors were selected for the patients. Platelet (median 11 vs 17 days) and neutrophil (median 14 vs 15 days) engraftment times were shorter in ATLG+ PTCy25 treated patients (both p < 0.05); veno-occlusive disease rates, graft failure and poor graft functions were similar between the two approaches (all p > 0.05); cumulative incidences of grade II-IV aGVHD at +100 days, grade III-IV aGVHD at +100 days, and grade II-IV cGVHD at 1-year were comparable between ATLG+PTCy25 and PTCy50 groups (all p > 0.05). Cumulative incidences of relapse and non-relapse mortality at 1-year were similar in two cohorts (both p > 0.05). PTCy50 was associated with a statistically significant benefit in terms of GVHD-free/relapse-free survival (GRFS) at 1-year (p = 0.03). Median GRFS was 115 (95% CI: 42–214) days and 248 (95% CI: 151-not reached) days, respectively [HR was 0.51 (0.28–0.95), p = 0.03; GRFS at 1-year was 20.7% vs 44.3%, respectively]. However, the groups were comparable in terms of PFS and OS. Median PFS was 332 days (95% CI: 182 days-not reached) for ATLG+PTCy25 group. It was not reached (95% CI: 210 days-not reached) for the patients who received PTCy50. Median OS was not reached in either ATLG+PTCy25 (95% CI: 191 days-not reached) or PTCy50 groups (Log rank = 0.42). Our study showed that lowering PTCy dose with ATLG seems to accelerate platelet and neutrophil engraftment rates; confers similar survival and relapse rates, similar acute and chronic GVHD frequency despite increased GRFS at 1-year.